194 related articles for article (PubMed ID: 23817696)
1. Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma.
Chantzi NI; Tiniakos DG; Palaiologou M; Goutas N; Filippidis T; Vassilaros SD; Dhimolea E; Mitsiou DJ; Alexis MN
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1489-98. PubMed ID: 23817696
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptors β1 and β2 are associated with distinct responses of estrogen receptor α-positive breast carcinoma to adjuvant endocrine therapy.
Dhimolea E; Tiniakos DG; Chantzi ΝΙ; Goutas N; Vassilaros SD; Mitsiou DJ; Alexis ΜN
Cancer Lett; 2015 Mar; 358(1):37-42. PubMed ID: 25524554
[TBL] [Abstract][Full Text] [Related]
3. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers.
Yan M; Rayoo M; Takano EA; ; Fox SB
Breast Cancer Res Treat; 2011 Apr; 126(2):395-405. PubMed ID: 20490651
[TBL] [Abstract][Full Text] [Related]
4. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.
Shaaban AM; Green AR; Karthik S; Alizadeh Y; Hughes TA; Harkins L; Ellis IO; Robertson JF; Paish EC; Saunders PT; Groome NP; Speirs V
Clin Cancer Res; 2008 Aug; 14(16):5228-35. PubMed ID: 18698041
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions.
Chantzi NI; Palaiologou M; Stylianidou A; Goutas N; Vassilaros S; Kourea HP; Dhimolea E; Mitsiou DJ; Tiniakos DG; Alexis MN
J Cancer Res Clin Oncol; 2014 Jun; 140(6):1057-66. PubMed ID: 24671226
[TBL] [Abstract][Full Text] [Related]
6. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
[TBL] [Abstract][Full Text] [Related]
7. The expression of estrogen receptors β2, 5 identifies and is associated with prognosis in non-small cell lung cancer.
Liu Z; Liao Y; Tang H; Chen G
Endocrine; 2013 Oct; 44(2):517-24. PubMed ID: 23475473
[TBL] [Abstract][Full Text] [Related]
8. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study.
Vinayagam R; Sibson DR; Holcombe C; Aachi V; Davies MP
BMC Cancer; 2007 Jul; 7():131. PubMed ID: 17640362
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.
Speirs V; Viale G; Mousa K; Palmieri C; Reed SN; Nicholas H; Cheang M; Jassem J; Lønning PE; Kalaitzaki E; van de Velde CJH; Rasmussen BB; Verhoeven DM; Shaaban AM; Bartlett JMS; Bliss JM; Coombes RC;
Ann Oncol; 2015 Sep; 26(9):1890-1897. PubMed ID: 26002610
[TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Expression Profiles of Cytoplasmic ERβ1 and Nuclear ERβ2 are Associated with Poor Outcomes following Radical Prostatectomy.
Schade GR; Holt SK; Zhang X; Song D; Wright JL; Zhao S; Kolb S; Lam HM; Levin L; Leung YK; Ho SM; Stanford JL
J Urol; 2016 Jun; 195(6):1760-6. PubMed ID: 26804755
[TBL] [Abstract][Full Text] [Related]
11. Different associations of estrogen receptor β isoforms, ERβ1 and ERβ2, expression levels with tumor size and survival in early- and late-onset breast cancer.
Mandusic V; Dimitrijevic B; Nikolic-Vukosavljevic D; Neskovic-Konstantinovic Z; Kanjer K; Hamann U
Cancer Lett; 2012 Aug; 321(1):73-9. PubMed ID: 22366496
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
13. ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid.
Meligova AK; Siakouli D; Stasinopoulou S; Xenopoulou DS; Zoumpouli M; Ganou V; Gkotsi EF; Chatziioannou A; Papadodima O; Pilalis E; Alexis MN; Mitsiou DJ
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835157
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.
Leung YK; Lam HM; Wu S; Song D; Levin L; Cheng L; Wu CL; Ho SM
Endocr Relat Cancer; 2010 Sep; 17(3):675-89. PubMed ID: 20501637
[TBL] [Abstract][Full Text] [Related]
15. Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer.
Davies MP; O'Neill PA; Innes H; Sibson DR; Prime W; Holcombe C; Foster CS
J Mol Endocrinol; 2004 Dec; 33(3):773-82. PubMed ID: 15591034
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer.
Ciucci A; Zannoni GF; Travaglia D; Petrillo M; Scambia G; Gallo D
Gynecol Oncol; 2014 Feb; 132(2):351-9. PubMed ID: 24378878
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of bcl-2 expression among women with breast cancer in Libya.
Ermiah E; Buhmeida A; Khaled BR; Abdalla F; Salem N; Pyrhönen S; Collan Y
Tumour Biol; 2013 Jun; 34(3):1569-78. PubMed ID: 23417836
[TBL] [Abstract][Full Text] [Related]
18. The potential role of estrogen receptor β2 in breast cancer.
Baek JM; Chae BJ; Song BJ; Jung SS
Int J Surg; 2015 Feb; 14():17-22. PubMed ID: 25450264
[TBL] [Abstract][Full Text] [Related]
19. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
20. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
